University of Arizona-Tuscon
Welcome,         Profile    Billing    Logout  
 6 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gerald, Lynn B
RELIANCE, NCT04069312: Roflumilast or Azithromycin to Prevent COPD Exacerbations

Recruiting
4
1250
US
Roflumilast, Daliresp, Azithromycin, Zithromax
Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
03/26
05/26
SOAR, NCT05722834: Self-regulation for Older Adults With Asthma Through Remote Education

Completed
N/A
20
US
SOAR intervention
University of Michigan, American Lung Association
Asthma
05/24
05/24
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
Dransfield, Mark
NCT06376994: Multi-Center Clean Air Randomized Controlled Trial in COPD

Recruiting
3
770
US
Air cleaner, Sham air cleaner
JHSPH Center for Clinical Trials, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease (COPD)
09/27
09/28
NCT03085485: The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

Completed
2
40
US
Ivacaftor 150 MG, KALYDECO, Placebo
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI), Vertex Pharmaceuticals Incorporated
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
09/22
09/22
ATALANTa, NCT03679598: Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Hourglass Jul 2021 - Dec 2021 : From ATALANTA trial for alpha-1 antitrypsin deficiency
Completed
2
63
US
Alvelestat (MPH966), Placebo
University of Alabama at Birmingham, National Institutes of Health (NIH), Mereo BioPharma, National Center for Advancing Translational Sciences (NCATS)
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
11/23
12/23
DEPTH, NCT05382208: Doxycycline for Emphysema in People Living With HIV (The Trial)

Recruiting
2
250
US
Doxycycline, Placebo
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan
Emphysema, HIV
02/27
02/27
ZEVR, NCT04186546: Zephyr Valve Registry

Active, not recruiting
N/A
150
US
Zephyr Valve Procedure, Zephyr Endobronchial Valve, Endobronchial Valve, Bronchoscopic Lung Volume Reduction, BLVR
Pulmonx Corporation
Emphysema
12/24
12/26
DLP-LHC, NCT06177717: Deep Functional Phenotyping of the ALA Lung Health Cohort

Recruiting
N/A
1000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, University of Vermont
Lung Diseases
07/26
07/26
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
SPIROMICS, NCT01969344: Study of COPD Subgroups and Biomarkers

Active, not recruiting
N/A
2981
US
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), COPD Foundation, Columbia University, Johns Hopkins University, National Jewish Health, Temple University, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Francisco, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University
COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
12/30
12/30
SOURCE, NCT05033990: SPIROMICS Study of Early COPD Progression

Recruiting
N/A
1000
US
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina, Chapel Hill, Columbia University, Johns Hopkins University, National Jewish Health, University of Alabama at Birmingham, University of California, Los Angeles, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University Health Sciences, Temple University, University of California, San Francisco, COPD Foundation, Mayo Clinic
COPD, Early-Onset
01/25
04/25
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
Wells, Michael L
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
Skeps, Raymond
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Active, not recruiting
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Active, not recruiting
2
395
US
MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Asthma
12/24
12/24
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26

Download Options